We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+5.95%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$7.75B
AUM Growth
+$180M
Cap. Flow
-$55.1M
Cap. Flow %
-0.71%
Top 10 Hldgs %
15.53%
Holding
560
New
192
Increased
91
Reduced
96
Closed
133

Sector Composition

Rank Sector Weight
1 Technology 21.47%
2 Industrials 15.13%
3 Healthcare 14.64%
4 Financials 8.83%
5 Consumer Discretionary 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DCPH
276
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.14M 0.04%
139,191
+85,910
+161% +$2.01M
OFG icon
277
OFG Bancorp
OFG
$2.21B
$3.12M 0.04%
+131,170
New +$2.61M
GNMK
278
DELISTED
GenMark Diagnostics, Inc
GNMK
$3.07M 0.04%
473,442
+30,300
+7% +$214K
NFH
279
CALL
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$3.02M 0.04%
300,000
EGHT icon
280
8x8 Inc
EGHT
$332M
$3.02M 0.04%
125,279
-501,135
-80% -$11.7M
COUP
281
DELISTED
Coupa Software Incorporated
COUP
$3.01M 0.04%
+23,797
New +$2.55M
ITB icon
282
iShares US Home Construction ETF
ITB
$2.35B
$3M 0.04%
+78,526
New +$2.97M
LCAHU
283
DELISTED
Landcadia Holdings II, Inc. Unit
LCAHU
$3M 0.04%
+300,000
New +$3.01M
REAL icon
284
The RealReal
REAL
$1.5B
$2.99M 0.04%
+103,365
New +$2.99M
YETI icon
285
Yeti Holdings
YETI
$3.95B
$2.97M 0.04%
+102,566
New +$2.95M
SYRS
286
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.94M 0.04%
+31,747
New +$2.21M
TCDA
287
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.93M 0.04%
74,275
+49,399
+199% +$1.74M
DOCU
288
DocuSign
DOCU
$11.5B
$2.92M 0.04%
58,805
-47,631
-45% -$2.54M
KNSA icon
289
Kiniksa Pharmaceuticals
KNSA
$5.93B
$2.88M 0.04%
212,621
+81,119
+62% +$1.26M
CNDT icon
290
Conduent
CNDT
$264M
$2.88M 0.04%
+300,000
New +$3.24M
ZWS icon
291
Zurn Elkay Water Solutions
ZWS
$8.53B
$2.8M 0.04%
+192,582
New +$2.59M
TOVX icon
292
CALL
Theriva Biologics
TOVX
$10.1M
$2.75M 0.04%
20,000
ZBH icon
293
Zimmer Biomet
ZBH
$18.4B
$2.66M 0.03%
23,235
-311,687
-93% -$36.5M
MANU icon
294
Manchester United
MANU
$3.73B
$2.64M 0.03%
146,148
+46,849
+47% +$882K
RWGE
295
CALL
DELISTED
Regalwood Global Energy Ltd. Class A Ordinary Shares
RWGE
$2.55M 0.03%
250,001
DEACU
296
DELISTED
Diamond Eagle Acquisition Corp. Unit
DEACU
$2.52M 0.03%
+250,000
New +$2.51M
IMTX icon
297
CALL
Immatics
IMTX
$1.32B
$2.5M 0.03%
250,000
MOTS
298
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$2.42M 0.03%
+2,668
New +$2.98M
PLMR icon
299
Palomar
PLMR
$3.45B
$2.41M 0.03%
+100,153
New +$2.2M
UTI icon
300
Universal Technical Institute
UTI
$1.59B
$2.4M 0.03%
700,219
+96,400
+16% +$327K

Similar funds

Alyeska Investment Group's Q2 2019 Portfolio in Review

As of Q2 2019, Alyeska Investment Group held 560 positions worth $7.75B, up 2.4% from $7.57B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Alyeska Investment Group's Q2 2019 filing shows 192 new, 91 increased, 96 reduced and 133 closed positions. Its largest new stake was Uber: 2,870,924 shares worth $133M. The largest sale was Intel, an estimated $143M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Industrials and Healthcare.

  • Alyeska Investment Group's largest Q2 2019 buy was Uber: 2,870,924 shares worth $133M.
  • Alyeska Investment Group added most to NXP Semiconductors in Q2 2019, an estimated $91M increase.
  • Alyeska Investment Group's biggest Q2 2019 reduction was Activision Blizzard, cutting an estimated $64.8M.
  • Alyeska Investment Group fully exited Intel in Q2 2019, selling an estimated $143M.
  • Alyeska Investment Group's ten largest holdings make up 16% of its $7.75B portfolio in Q2 2019.
  • Alyeska Investment Group opened 192 new positions and closed 133 in Q2 2019.
  • Alyeska Investment Group's portfolio value rose 2.4% quarter-over-quarter to $7.75B.

Based on Alyeska Investment Group's 13F filing for Q2 2019, filed 14 Aug 2019.